Adebrelimab and Chidamide for Pancreatic Cancer

Pancreatic cancer is a kind of digestive system tumor with high malignant degree and poor prognosis. Most patients with pancreatic cancer are locally advanced or have distant metastases at the time of diagnosis, so it is extremely important to find effective drugs to control tumor metastasis. There are few approved first-line treatment options for metastatic pancreatic cancer. The FOLFIRINOX regimen (Irinotecan combined with Oxaliplatin and 5FU/LV) is recommended as a first-line treatment for patients with good overall performance status (ECOG 0-1), with a median overall survival of approximately 11.1 months. For patients with ECOG 0-2, the combination of Gemcitabine and Albumin-bound Paclitaxel is an option for first-line chemotherapy, with a median survival of 8.5 months. Single-agent Gemcitabine or S-1 is the standard first-line treatment for patients with poor overall performance status, resulting in a median survival of approximately 6 to 9 months. Therefore, for pancreatic cancer patients, the efficacy of existing first-line treatment regimens has reached a bottleneck, highlighting the urgent need to explore new first-line combination therapy options. Immunotherapy has demonstrated significant advantages in solid tumors, however, its application in pancreatic ductal adenocarcinoma (PDAC) has been disappointing to date. Although several promising preclinical studies have been conducted, translating these findings into clinical research remains challenging, likely due to the complex immunosuppressive tumor microenvironment of PDAC. Therefore, this study aims to evaluate the efficacy and safety of Adebrelimab and Chidamide in Combination with Gemcitabine and S1 as first-line treatment for locally advanced or metastatic pancreatic cancer.